Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Tigan
Overview
What is Tigan?
Chemically, trimethobenzamide HCl is N-[p-[2-(dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxybenzamide monohydrochloride. Ithas a molecular weight of 424.93 and the following structural formula:
Single-Dose Vials
Multi-Dose Vials
What does Tigan look like?
What are the available doses of Tigan?
Sorry No records found.
What should I talk to my health care provider before I take Tigan?
Sorry No records found
How should I use Tigan?
Tigan
(See and .)Dosage should be adjusted according to the indication for therapy, severity of symptoms and the response of the patient.
Geriatric Patients
CLINICAL PHARMACOLOGY and PRECAUTIONS
Patients with Renal Impairment
CLINICAL PHARMACOLOGY and
DOSAGE AND ADMINISTRATION
INJECTABLE, 100 mg/mL (Not for use in pediatric patients)
NOTE
Intramuscular administration may cause pain, stinging, burning, redness and swelling at the site of injection. Such effects may beminimized by deep injection into the upper outer quadrant of the gluteal region, and by avoiding the escape of solution along the route.
What interacts with Tigan?
Sorry No Records found
What are the warnings of Tigan?
Sorry No Records found
What are the precautions of Tigan?
Sorry No Records found
What are the side effects of Tigan?
Sorry No records found
What should I look out for while using Tigan?
The injectable form of Tigan® is contraindicated in pediatric patients and in patients with known hypersensitivity totrimethobenzamide.
Tigan
Usage in Pregnancy
Usage with Alcohol
Tigan
What might happen if I take too much Tigan?
Sorry No Records found
How should I store and handle Tigan?
Voriconazole tablets should be stored at 15° – 30°C (59° – 86°F) [see USP Controlled Room Temperature].Voriconazole powder for Oral Suspension should be stored at 2° – 8°C (36°– 46° F) (in a refrigerator) before reconstitution. The shelf-life of the powder for oral suspension is 24 months.The reconstituted suspension should be stored at 15° – 30°C (59° – 86°F) [see USP Controlled Room Temperature]. Do not refrigerate or freeze. Keep the container tightly closed. The shelf-life of the reconstituted suspension is 14 days. Any remaining suspension should be discarded 14 days after reconstitution.Voriconazole tablets should be stored at 15° – 30°C (59° – 86°F) [see USP Controlled Room Temperature].Voriconazole powder for Oral Suspension should be stored at 2° – 8°C (36°– 46° F) (in a refrigerator) before reconstitution. The shelf-life of the powder for oral suspension is 24 months.The reconstituted suspension should be stored at 15° – 30°C (59° – 86°F) [see USP Controlled Room Temperature]. Do not refrigerate or freeze. Keep the container tightly closed. The shelf-life of the reconstituted suspension is 14 days. Any remaining suspension should be discarded 14 days after reconstitution.Voriconazole tablets should be stored at 15° – 30°C (59° – 86°F) [see USP Controlled Room Temperature].Voriconazole powder for Oral Suspension should be stored at 2° – 8°C (36°– 46° F) (in a refrigerator) before reconstitution. The shelf-life of the powder for oral suspension is 24 months.The reconstituted suspension should be stored at 15° – 30°C (59° – 86°F) [see USP Controlled Room Temperature]. Do not refrigerate or freeze. Keep the container tightly closed. The shelf-life of the reconstituted suspension is 14 days. Any remaining suspension should be discarded 14 days after reconstitution.Tigan® (trimethobenzamide hydrochloride) is available as follows:NDC 42023-119-25 100 mg/mL in 2 mL Single-Dose Vials, Pack of 25NDC 42023-118-01 100 mg/mL in 20 mL Multi-Dose Vials, Pack of 1Rx OnlyManufacturered by:Par PharmaceuticalChestnut Ridge, NYR04/163000358FOS118J-01-90-01Tigan® (trimethobenzamide hydrochloride) is available as follows:NDC 42023-119-25 100 mg/mL in 2 mL Single-Dose Vials, Pack of 25NDC 42023-118-01 100 mg/mL in 20 mL Multi-Dose Vials, Pack of 1Rx OnlyManufacturered by:Par PharmaceuticalChestnut Ridge, NYR04/163000358FOS118J-01-90-01Tigan® (trimethobenzamide hydrochloride) is available as follows:NDC 42023-119-25 100 mg/mL in 2 mL Single-Dose Vials, Pack of 25NDC 42023-118-01 100 mg/mL in 20 mL Multi-Dose Vials, Pack of 1Rx OnlyManufacturered by:Par PharmaceuticalChestnut Ridge, NYR04/163000358FOS118J-01-90-01Tigan® (trimethobenzamide hydrochloride) is available as follows:NDC 42023-119-25 100 mg/mL in 2 mL Single-Dose Vials, Pack of 25NDC 42023-118-01 100 mg/mL in 20 mL Multi-Dose Vials, Pack of 1Rx OnlyManufacturered by:Par PharmaceuticalChestnut Ridge, NYR04/163000358FOS118J-01-90-01Tigan® (trimethobenzamide hydrochloride) is available as follows:NDC 42023-119-25 100 mg/mL in 2 mL Single-Dose Vials, Pack of 25NDC 42023-118-01 100 mg/mL in 20 mL Multi-Dose Vials, Pack of 1Rx OnlyManufacturered by:Par PharmaceuticalChestnut Ridge, NYR04/163000358FOS118J-01-90-01Tigan® (trimethobenzamide hydrochloride) is available as follows:NDC 42023-119-25 100 mg/mL in 2 mL Single-Dose Vials, Pack of 25NDC 42023-118-01 100 mg/mL in 20 mL Multi-Dose Vials, Pack of 1Rx OnlyManufacturered by:Par PharmaceuticalChestnut Ridge, NYR04/163000358FOS118J-01-90-01Tigan® (trimethobenzamide hydrochloride) is available as follows:NDC 42023-119-25 100 mg/mL in 2 mL Single-Dose Vials, Pack of 25NDC 42023-118-01 100 mg/mL in 20 mL Multi-Dose Vials, Pack of 1Rx OnlyManufacturered by:Par PharmaceuticalChestnut Ridge, NYR04/163000358FOS118J-01-90-01Tigan® (trimethobenzamide hydrochloride) is available as follows:NDC 42023-119-25 100 mg/mL in 2 mL Single-Dose Vials, Pack of 25NDC 42023-118-01 100 mg/mL in 20 mL Multi-Dose Vials, Pack of 1Rx OnlyManufacturered by:Par PharmaceuticalChestnut Ridge, NYR04/163000358FOS118J-01-90-01Tigan® (trimethobenzamide hydrochloride) is available as follows:NDC 42023-119-25 100 mg/mL in 2 mL Single-Dose Vials, Pack of 25NDC 42023-118-01 100 mg/mL in 20 mL Multi-Dose Vials, Pack of 1Rx OnlyManufacturered by:Par PharmaceuticalChestnut Ridge, NYR04/163000358FOS118J-01-90-01Tigan® (trimethobenzamide hydrochloride) is available as follows:NDC 42023-119-25 100 mg/mL in 2 mL Single-Dose Vials, Pack of 25NDC 42023-118-01 100 mg/mL in 20 mL Multi-Dose Vials, Pack of 1Rx OnlyManufacturered by:Par PharmaceuticalChestnut Ridge, NYR04/163000358FOS118J-01-90-01
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Mechanism of Action
The mechanism of action of Tigan® as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), anarea in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomitingcenter apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine isinhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.
Pharmacokinetics
The pharmacokinetics of trimethobenzamide have been studied in healthy adult subjects. Following administration of 200 mg(100 mg/mL) Tigan I.M. injection, the time to reach maximum plasma concentration (Tmax) was about half an hour, about 15minutes longer for Tigan 300 mg oral capsule than an I.M. injection. A single dose of Tigan 300 mg oral capsule provided a plasmaconcentration profile of trimethobenzamide similar to Tigan 200 mg I.M. The relative bioavailability of the capsule formulationcompared to the solution is 100%. The mean elimination half-life of trimethobenzamide is 7 to 9 hours. Between 30 – 50% of a singledose in humans is excreted unchanged in the urine within 48 – 72 hours. The metabolic disposition of trimethobenzamide in humans isnot known. Specifically, it is not known if active metabolites are generated in humans.
Special Populations
PRECAUTIONS: General and DOSAGE AND ADMINISTRATION
Gender
Race
PRECAUTIONS: General and DOSAGE AND
ADMINISTRATION
Non-Clinical Toxicology
The injectable form of Tigan® is contraindicated in pediatric patients and in patients with known hypersensitivity totrimethobenzamide.Tigan
Usage in Pregnancy
Usage with Alcohol
Tigan
Thiazides may add to or potentiate the action of other antihypertensive drugs. See for concomitant use with other antihypertensive drugs.
The effect of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary.
Triamterene and hydrochlorothiazide capsules, USP may raise the level of blood uric acid; dosage adjustments of antigout medication may be necessary to control hyperuricemia and gout.
The following agents given together with triamterene may promote serum potassium accumulation and possibly result in hyperkalemia because of the potassium-sparing nature of triamterene, especially in patients with renal insufficiency: blood from blood bank (may contain up to 30 mEq of potassium per liter of plasma or up to 65 mEq per liter of whole blood when stored for more than 10 days); low-salt milk (may contain up to 60 mEq of potassium per liter); potassium-containing medications (such as parenteral penicillin G potassium); salt substitutes (most contain substantial amounts of potassium).
Exchange resins, such as sodium polystyrene sulfonate, whether administered orally or rectally, reduce serum potassium levels by sodium replacement of the potassium; fluid retention may occur in some patients because of the increased sodium intake.
Chronic or overuse of laxatives may reduce serum potassium levels by promoting excessive potassium loss from the intestinal tract; laxatives may interfere with the potassium-retaining effects of triamterene.
The effectiveness of methenamine may be decreased when used concurrently with hydrochlorothiazide because of alkalinization of the urine.
During the course of acute febrile illness, encephalitides, gastroenteritis, dehydration and electrolyte imbalance, especially inchildren and the elderly or debilitated, CNS reactions such as opisthotonos, convulsions, coma and extrapyramidal symptoms havebeen reported with and without use of ® (trimethobenzamide hydrochloride) or other antiemetic agents. In such disorderscaution should be exercised in administering ®, particularly to patients who have recently received other CNS-acting agents(phenothiazines, barbiturates, belladonna derivatives). Primary emphasis should be directed toward the restoration of body fluids andelectrolyte balance, the relief of fever and relief of the causative disease process. Overhydration should be avoided since it may resultin cerebral edema.The antiemetic effects of ® may render diagnosis more difficult in such conditions as appendicitis and obscure signs of toxicitydue to overdosage of other drugs.
General
Adjustment of Dose in Renal FailureA substantial route of elimination of unchanged trimethobenzamide is via the kidney. Dosage adjustment should be considered inpatients with reduced renal function including some elderly patients. (See ).
Geriatric Use
Clinical studies of trimethobenzamide hydrochloride did not include sufficient numbers of patients aged 65 and over to determinewhether they respond differently from younger patients. Although there are studies reported in the literature that included elderlypatients greater than 65 years old with younger patients, it is not known if there are differences in efficacy or safety parameters for elderly andnon-elderly patients treated with trimethobenzamide. In general, dose selection for an elderly patient should be cautious, usuallystarting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and ofconcomitant disease or other drug therapy.This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patientswith impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken indose selection, and it may be useful to monitor renal function. (See ).
There have been reports of hypersensitivity reactions and Parkinson-like symptoms. There have been instances of hypotensionreported following parenteral administration to surgical patients. There have been reports of blood dyscrasias, blurring of vision,coma, convulsions, depression of mood, diarrhea, disorientation, dizziness, drowsiness, headache, jaundice, muscle crampsand opisthotonos. If these occur, the administration of the drug should be discontinued. Allergic-type skin reactions have beenobserved; therefore, the drug should be discontinued at the first sign of sensitization. While these symptoms will usually disappearspontaneously, symptomatic treatment may be indicated in some cases.
For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS,
contact JHP at 1-866-923-2547 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.fda.gov/medwatch/.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).